The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex Times
Back to front
Eli Lilly outpaces Novo Nordisk in Q1 2026 results as obesity drug momentum diverges
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 11, 3:21 PM EDT

Eli Lilly outpaces Novo Nordisk in Q1 2026 results as obesity drug momentum diverges

In newly reported Q1 2026 updates, Eli Lilly showed sharply higher revenue and raised guidance, while Novo Nordisk posted an adjusted sales decline on a constant-currency basis, underscoring a widening gap in the pace of obesity-drug growth between the two leaders.

By The Apex Times Newsroom3 min readAI-assisted Apex article

Eli Lilly and Novo Nordisk both published Q1 2026 results that investors are using as competing read-throughs on demand for the blockbuster obesity and diabetes drug class centered on GLP-1 medicines. While both companies remain dominant in the obesity market, the latest figures point in different directions, according to a market report that framed the quarter as a meaningful divergence in the so-called GLP-1 duopoly.

Eli Lilly reported revenue growth of 55.5% in the quarter, and the report said the company also raised its guidance. Guidance is management’s forward-looking estimate of expected performance, and increases typically announcement confidence in product demand, manufacturing delivery, and pricing or mix versus prior expectations.

Novo Nordisk, by contrast, reported an adjusted sales decline of 4% on a constant-currency basis, the report said. Constant currency is a way of measuring sales performance while removing the impact of foreign exchange rate changes, so a decline there is intended to reflect underlying demand and commercial execution rather than currency swings.

Taken together, the results suggest that Eli Lilly’s operating momentum improved faster than the market had come to expect, while Novo Nordisk faced more headwinds in the quarter. The market framing also implied that the two companies’ trajectories were no longer moving in tandem, a shift that can influence expectations for market share, pricing dynamics, and the timing of new product expansion.

The obesity-drug business has become a focal point for healthcare investors because it links high-revenue categories to long-term treatment growth. GLP-1 medicines, which help regulate appetite and blood sugar, have moved from specialty use into broader obesity treatment pathways, and both companies have spent heavily to expand capacity and deepen commercialization.

Even with the duopoly still intact, small differences in growth rates can matter. Higher growth can allow a company to invest more aggressively in next-generation formulations, supply expansion, and payer contracting, while weaker performance can raise questions about near-term execution or market timing.

The companies did not disclose in the cited market report any additional operational details beyond the headline growth and the direction of guidance for Lilly, and the adjusted constant-currency sales change for Novo Nordisk. Without access to the underlying earnings releases and filings in this reporting set, it is not possible to attribute the differences to specific drivers such as prescription trends, inventory normalization, regional performance, or competitive positioning.

What to watch next is whether Lilly’s raised guidance holds up across subsequent quarters and whether Novo Nordisk can stabilize or reverse the adjusted sales decline. Traders and long-term investors will likely focus on new quarter updates, management commentary on demand and supply, and any changes to pricing, reimbursement, or product mix that could explain the gap emerging between the two leaders. Next earnings and updated forecasts will be the clearest checkpoints.

Why It Matters

  • A faster growth profile at Lilly versus a decline at Novo can shift investor expectations for obesity-drug leadership and near-term market share.
  • Raised guidance typically indicates improved confidence in demand and execution, which can affect how investors price future cash flows.
  • Adjusted constant-currency declines at Novo highlight that the weak quarter may reflect underlying performance rather than currency effects.
  • The next set of earnings and updated guidance will likely determine whether the divergence persists or proves temporary.

Sources

Key Facts

  • A market report described Q1 2026 results for Eli Lilly and Novo Nordisk as showing diverging momentum in obesity-related GLP-1 medicines.
  • Eli Lilly reported Q1 2026 revenue growth of 55.5%.
  • The same report said Eli Lilly raised its guidance for future performance.
  • Novo Nordisk reported an adjusted sales decline of 4% on a constant-currency basis in Q1 2026.
  • The market report characterized the combined results as separating the GLP-1 duopoly’s trajectories rather than keeping them aligned.

Healthcare Related

Eli Lilly outpaces Novo Nordisk in Q1 2026 results as obesity drug momentum diverges | The Apex Times